Money & Investing
219,826 members
From personal finance tips to halal investment strategies, we're here to help you navigate the world of money 💸 Muzz takes no responsibility for the accuracy or uptake of financial advice shared in this group.
@LearnerPractitioner
I thought astrology, zodiac sign were fake, till I discover it's billion plus Dollar industry...
I believe in cash, 🫣 so I believe in it now
@chen3
Maybe someone who's shop or anywork available for me can I apply
@LearnerPractitioner
Why unwritten rules are far more powerful than written rules?
@fawaz_dev
Black Monday Never Showed Up. The Bond Market Did.
https://fawazmk.substack.com/p/black-monday-never-showed-up-the?utm_source=share&utm_medium=android&r=4kyrxe
Are people still invested in the stock market?
@RD21Y88
Disappointment is a sort of bankruptcy - the bankruptcy of a soul that expends too much in hope and expectation.
@Khalil1083
Oral hair loss treatment
I had some money on this before the trial results came. It’s gone up 20% plus and still rising .
Biotech risky but when it succeeeds does v well..
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01
VDPHL01 demonstrated increases in target area hair count (TAHC) of 28.6 hairs/cm² (once-daily dosing; p<0.0001) and 36.4 hairs/cm² (twice-daily dosing; p<0.0001) versus 6.6 hairs/cm² for placebo at Month 6, a similar mean increase in TAHC that was observed in Study ‘302’
Approximately 78.8% (QD) and 85.0% (BID) of participants reported visible improvement in patient-reported outcomes (PRO) versus 35.3% of placebo participants; 55.7% (QD; p<0.0001) and 68.7% (BID; p<0.0001) of participants reported ‘improved’ or ‘much improved’ outcomes at Month 6 versus 15.0% of placebo participants
Onset of hair growth was observed with statistically significant separation from placebo in non-vellus TAHC, PRO, and Investigator Global Assessment (IGA) at Month 2, the earliest time point evaluated
VDPHL01 demonstrated a favorable safety and tolerability profile in more than 1,000 participants across two registration-directed studies with no new safety signals emerging in Study ‘304’
These results combined with previously reported positive topline findings from Part A of the Phase 2/3 clinical trial (Study ‘302’) represent the full placebo-controlled data set to support the potential for VDPHL01 to become the first FDA-approved non-hormonal oral treatment for the 50 million men with pattern hair loss in the U.S.
@Dodo7597221
Hi💗
@Abdo27529663
🌹❤️
@amira19003977
Hi